ReviewNeuronal signaling2023
Cytokine activity in Parkinson's disease.
Review in Neuronal signaling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 44 citations in OpenAlex.
- Effects of Meditation and Yoga on Anxiety, Depression and Chronic Inflammation in Patients with Parkinson's Disease: A Randomized Clinical Trial.Psychotherapy and psychosomatics · 2025Trial
- Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies.Neural regeneration research · 2026Article
- Complement dysregulation during the early phases of synucleinopathy.Acta neuropathologica · 2026Article
- Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.Brain, behavior, & immunity - health · 2026Article
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Regulator of G protein signaling 10: a critical regulator of chronic systemic inflammation in parkinson's disease.Journal of neuroinflammation · 2026Review
- High intensity interval training for Parkinson's disease: A scoping review of systemic effects and physiological adaptations.Journal of Parkinson's disease · 2026Article
- Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Potential common pathogenesis of several neurodegenerative diseases.Neural regeneration research · 2026Article
- Single-cell analysis of the peripheral immune landscape in Parkinson's disease: insights into dendritic cell and CD4+ T-cell transcriptomics.NPJ Parkinson's disease · 2026Article
- Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association.Frontiers in aging neuroscience · 2026Article
- Crossroads of well-being: oral health, neurology, neuronutrition and healthy aging.Open medicine (Warsaw, Poland) · 2026Review
- A neuroimmune-enriched multibiofluid proteomic index associated with cognitive-motor progression in early Parkinson's disease: a longitudinal PPMI cohort study.Frontiers in immunology · 2026Article
- Pathogen Antibodies and Parkinson's Disease: A Two-sample Mendelian Randomization Study.Current neurovascular research · 2026Article
- Modulation of Behavioral, Biochemical, Immunomodulatory, and Transcriptional Profiles by the StrainInternational journal of molecular sciences · 2025Article
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- IL-1b and TNF-a-driven sleep alterations: Neuroimmune mechanisms and behavioral implications.Brain, behavior, & immunity - health · 2025Review
- High-throughput cytokine detection platform for evaluation of chemical induced microglial activation.SLAS technology · 2025Article
- Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Interferon gamma stimulates coordinated changes in LRRK2, GCase, and cathepsin activities in idiopathic and genetic Parkinson's disease monocytes.NPJ Parkinson's disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contribution of the immune system to the pathophysiology of neurodegenerative Parkinson's disease (PD) is increasingly being recognised, with alterations in the innate and adaptive arms of the immune system underlying central and peripheral inflammation in PD. As chief modulators of the immune response, cytokines have been intensely studied in the field of PD both in terms of trying to understand their contribution to disease pathogenesis, and if they may comprise much needed therapeutic targets for a disease with no current modifying therapy. This review summarises current knowledge on key cytokines implicated in PD (TNFα, IL-6, IL-1β, IL-10, IL-4 and IL-1RA) that can modulate both pro-inflammatory and anti-inflammatory effects. Cytokine activity in PD is clearly a complicated process mediated by substantial cross-talk of signalling pathways and the need to balance pro- and anti-inflammatory effects. However, understanding cytokine activity may hold promise for unlocking new insight into PD and how it may be halted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.